• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Encapsulated islet transplantation for patients with type 1 diabetes mellitus

    2016-11-12 01:43:34MeirigengQiShusenWangYongWangDepartmentofTranslationalResearchandCellularTherapeuticsDiabetesandMetabolicResearchInstituteBeckmanResearchInstituteoftheCityofHopeDuarteCAUSAOrganTransplantCenterTianjinFirstCenterHospital
    實用器官移植電子雜志 2016年6期

    Meirigeng Qi,Shusen Wang,Yong Wang(. Department of Translational Research and Cellular Therapeutics,Diabetes and Metabolic Research Institute,Beckman Research Institute of the City of Hope,Duarte,CA,USA ;2. Organ Transplant Center,Tianjin First Center Hospital,Tianjin 30092,China ;3. Key Laboratory for Critical Care Medicine of the Ministry of Health,Tianjin First Central Hospital,Tianjin 30000,China ;. Division of Transplantation/Department of Surgery,University of Illinois at Chicago,Chicago,IL,USA

    【Abstract】 Encapsulation of pancreatic islets has been investigated for over three decades to advance islet transplantation outcomes and to defecate the side effects of immunosuppressive medications. Within the numerous encapsulation systems developed, microencapsulation has been investigated most extensively so far. A lot of materials have been used for microencapsulation in different animal models(including non-human primates or NHPs)and some materials have shown to be of immunoprotection to islet grafts without the need for immunosuppression. In spite of the initial success of microcapsules in NHP models,the combined use of islet transplantation(allograft)and microencapsulation has not yet been successful in clinical trials. This concise review consists of two sections∶Brief summary for transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus(T1DM), and present challenges and future perspectives.

    【Key words】 T1DM;Islet transplantation;Microencapsulation

    Introduction

    Type 1 diabetes mellitus(T1DM),also known as insulin-dependent diabetes mellitus,is an autoimmune disease that causes a progressive destruction of the insulin-producing pancreatic β-cells1-2. As a result,patients require exogenous insulin to maintain normal blood glucose levels. In patients with T1DM,long-termhyperglycemia often causes complications such as nephropathy,neuropathy,and retinopathy. According to a report from the American Diabetes Association(ADA),there are nearly three million children and adults living with T1DM in the U.S. and millions of others affected worldwide3.Management of T1DM and other associated complications are burdensome to both individuals and to society as a whole. Insulin injection is a common method to directly control blood glucose levels. However,intensive insulin therapy can induce more frequent episodes of hypoglycemic symptoms in certain populations of patients with T1DM4-5.Islet transplantation is considered as an improved way to cure T1DM in comparison with insulin injection and whole pancreas transplantation. Absence of insulin in patients with T1DM forces them to use exogenous insulin to maintain normal blood glucose,which can delay or prevent health complications. Theoretically,exogenous insulin can replace β- cells in islets,but practically,the insulin injection cannot maintain stable blood glucose levels. Pancreatic islet transplantation is a procedure to selectively transplant the endocrine part of a whole pancreas(about 2% of the pancreas mass).In comparison with whole pancreas transplantation,islet transplantation can be conducted via a minimally invasive approach and is associated with minimal or no complications. The islets can be infused via a catheter that has percutaneous portal venous access6.Therefore this procedure can be applied to a wider range of recipients. More importantly,the islet transplantation can provide glycemic control without exogenous insulin and risks of hypoglycemia. The first experimental islet transplantation was conducted in a rodent model in 1972,several years after this a whole pancreas transplantation was initiated in a human patient7. Although islet transplantation has been widely accepted in recent years,the protocol has not obtained a license and is not accepted as a standard clinical treatment. Currently,many islet transplantation centers are planning or initiating license applications for clinical allogeneic islet transplantation.

    Transplantation of encapsulated pancreatic islets as a treatment for patients with T1MD

    Overview of encapsulation

    Cell encapsulation technology is based on the concept of immunoisolation,which was originally presented by Prehn et al. From as early as 1954,Prehn et al.used a type of immunoisolation instrument called the diffusion chamber device8. In that study,the diffusion chamber device was used to prevent the homograft from provoking an immune reaction in the host. Later on this technology was used to protect transplanted cells,known as “artificial cells”9-10. Since islet cells can be isolated and transplanted successfully,the encapsulation technology was soon applied in the field of islet transplantation. Many types of encapsulation technologies have been designed over the last three decades(Figure 1)and investigated in different animals such as mice11,rats12,dogs13-14,and monkeys15-16. These studies demonstrate the feasibility of restoring normoglycemia by implanting allo- and xenografts without immunosuppression. Furthermore,the studies reveal the inconsistency of transplantation outcomes due to differences in encapsulation strategy and in animal models. The studies also suggest that long-term graft survival might depend on enriched and consistent blood supply to the grafts. In the light of the experiences accumulated from the large amount of transplant studies performed in different animal models,scientists and clinicians attempted a trial involving encapsulated allogeneic islet transplantation in patients with T1DM17-20. The following sections address microencapsulation,depict immunology and biocompatibility factors of the devices,outline the approach of local/short-term immunomodulation,and report the trials of clinical encapsulated islet transplantation.

    Microencapsulation

    The main advantages of the microencapsulation system over other encapsulation technologies are its stable mechanical structure,large surface areato-volume ratio,and improved diffusion profile.Due to the flexible and adjustable characteristics,the microcapsules are mostly fabricated from hydrogels. Over the past 30 years,hydrogel including alginate21,poly(hydroxyethyl methacrylate-methyl methacrylate),agarose22,acrylonitrile copolymers,chitosan23,and polyethelene glycol(PEG)24have been frequently used for microencapsulation. To date,the most preferable material for microencapsulation is alginate. The principle of making microcapsules is based on the envelopment of individual islets in a droplet,which is transformed into a rigid capsule by gelification(in the case of alginate beads)followed by polycation coating(in the case of multiple-layered microcapsules).

    Figure 1 Schematic representation of immunoisolation device or bioartificial pancreas. They can be commonly separated into two categories,intravascular and extravascular device. The latter can further be divided into macroencapsulation and microencapsulation devices.Intravascular and extravascular classifications are based on whether or not it is connected directly to the blood circulation. The macroencapsulation and microencapsulation classifications depend on whether it contains one or more islets in the inside

    Alginate,a collective term for a family of polysaccharides synthesized by seaweed and bacteria,is used in a wide range of foods,pharmaceutical products,and other applications25. In molecular terms,alginates are binary linear polysaccharides composed of two monomers,α-L-guluronic(G)and β-D-mannuronic(M)acid,which form M blocks,G blocks,and blocks of alternating sequence(MG)26.In nature,alginates are found to exhibit great variations in composition and arrangement of the two monomers in a polymer chain. Blocks of repeating G units(G blocks)form cavities that bind divalent cations,which cross-link G blocks of other alginate chains27.This in turn allows for the formation of gels as capsules.Hence,G-block sequences are required for the alginate to form a strong gel with divalent ions such as Ca2+,Ba2+and Sr2+. A strong correlation therefore exists between the sequential structure and functional properties of alginates.

    To increase the stability and to reduce the permeability of alginate gel beads,a polycation layer is traditionally added to the alginate gel core28-30. However,the successful use of alginate-polycation capsules as carriers for insulin producing cells in vivo has been hampered by the capsule's lack of biocompatibility as well as their mechanical instability. These disadvantages have made controlled insulin release and immunoprotection of islets difficult to achieve.The major obstacle for stability is swelling,causing an increase in pore size and ultimately breakage. This is caused by the loss of calcium from the calcium-alginate gel by e.g. phosphate and citrate,which can bind calcium,and non-gelling ions such as sodium that over time will exchange some of the calcium in the gel31.

    Immunology and biocompatibility

    Demographics and baseline characteristics within clinical status groups

    Immunology studies the host's defense mechanisms against invasion of foreign organisms; either living or non-living. The immune response is often divided into two categories,innate and acquired immune reaction. The innate immune response is non-specific and exists in all individuals. It doesn't distinguish between different organisms and acts rapidly upon the exposure of foreign invaders. The innate immune reaction typically initiates with cellular mediators such as macrophages and neutrophils. The acquired immune reaction is specific and not actively present in all individuals. This specific immune response requires the recognition of a specific antigen by lymphocytes including T and B cells.

    Biomaterials are not firmly considered as organisms32,however implantation of biomaterials in a host triggers an immune reaction,which involves many components of the immune system. Biocompatibility is commonly defined as the ability of a biomaterial or other medical device to perform its function properly in a specific application with an appropriate response in the host33-34.“Biocompatibility refers to the ability of a biomaterial to perform its desired function with respect to a medical therapy,without eliciting any undesirable local or systemic effects in the recipients or beneficiary of that therapy,but generating the most appropriate beneficial cellular or tissue response in that specific situation,and optimizing the clinically relevant performance of that therapy”33. The immunoisolation device is not constructed solely by material for the main structure and it also contains islet cells. Therefore,in order for the device to be biocompatible,the bioartificial pancreas must carry out its proper function and it must not harm the host. For an immunoisolation device,biocompatibility has been referred to as the degree of fibrosis after implantation into the host. Recently work has focused on the implantation of microcapsules in larger animals,primarily NHPs,to evaluate the biocompatibility of the microcapsules for clinical islet transplantation.

    As noted earlier,alginate is the most commonly used material for islet microencapsulation. The biocompatibility of microcapsules has been tested with the implantation of empty microcapsules in numerous animal models. The peritoneal cavity has been selected as an optimal site for in vivo analysis of microencapsulated islet implantation,as this site can harbor a large volume of microcapsules7. This site is easily accessible during implantation and is relatively safe. It has been reported previously that empty microcapsules,composed of purified alginate,do not elicit any significant foreign body reaction after implantation into the peritoneal cavity of rodents35-36.However,implantation of empty microcapsules into the portal vein of pigs provoke extensive pericapsular cellular overgrowth37. This result indicates that portal vein microcapsule transplantation is incompatible with the current alginate composition.

    The evaluation of the function of microencapsulated islets in large animals is a necessary transit point between scientific studies in rodents and its clinical application for humans. Allotransplantation in large animals has been performed to mimic clinical islet transplantation. Soon-Shiong et al. initially reported the long-term reversal of diabetes in dogs using microencapsulated islet allografts38. Recently,allografts in alginate-PLL microcapsules were tested in the absence of anti-rejection medications in pigs but large-scale studies were not documented39.Wang et al. published work on the normalization of blood glucose levels in dogs for up to 214 days with a single transplantation of microencapsulated allogeneic islets without immunosuppressive medication13. Although the NHP is considered as an optimal allotransplantation model,little is published in terms of microencapsulated islet transplantation.In our previous study,we conducted allogeneic islet transplantations in baboons using the modified PMCG microcapsules. Two diabetic baboons were transplanted with an average of 16 475 IEQ/kg encapsulated islets(2-3 transplants)and neither baboon achieved normoglycemia after transplantation. Evenly distributed microcapsules were observed in the peritoneal cavity.Retrieved microcapsules at 4 weeks post-transplant were intact and free of cellular overgrowth around the microcapsules.

    Due to the shortage of donor tissues for patients with T1DM,xenotransplantation has drawn the attention of research facilities. Most xenotransplantation uses microencapsulated porcine islets as donor tissue.Sun et al. found that microencapsulated porcine islets transplanted into spontaneously diabetic cynomolgus monkeys survived for 120-800 days with no immunosuppression40. Other groups have tested their encapsulated porcine islets in non-diabetic monkeys15-16. It is notable that all of these transplanted porcine islets were encapsulated in alginate-polycation based microcapsules,which is a microcapsule with less antibody permeability.

    In our previous study,human islets encapsulated in Ca2+/Ba2+-alginate microbeads were transplanted into the peritoneal cavity of a diabetic baboon at a dose of 36 000 IEQ/kg. After transplantation,decreased blood glucose and positive C-peptide production were observed up to 2 weeks. Adhesion and clumping of the microcapsules were observed during laparotomy at day 76 post-transplant. Microcapsules that were retrieved at this point presented with fibrotic overgrowth.Xenogeneic tissue can trigger a stronger immune mediated rejection compared to allogeneic tissue,which may explain islet graft dysfunction in this study.Antibody responses against the encapsulated islets were found 20-35 days post-transplant. Similar results were observed in the transplantation of microencapsulated human islets into the peritoneal cavity of diabetic cynomolgus monkey(unpublished data).

    Local or short-term immunomodulation

    As mentioned earlier,a variety of natural and synthetic polymers have been used in islet encapsulation.However,inconsistency and poor long-term results have been a major limitation for clinical application.The graft failure is usually initiated by several factors including poor biocompatibility of the implanted materials,hypoxic conditions for islets inside of the capsules,and incomplete immunoprotection41-42. Thus,local or short-term immunomodulation and a non-systematic immunosuppressive treatment have been investigated to improve the encapsulated islet transplant outcomes.

    Biocompatibility of capsules is crucial for the long-term survival of the islet graft. Study showed that a 10-day immunosuppressive medication regimen significantly reduced the fibrotic overgrowth around the intraportally implanted empty microcapsules43. Our group also tested the beneficial effects of 2-week long T-cell directed immunosuppressive medication and anti-inflammatory agents(TNF-α blocker)on the biocompatibility of Ca2+/Ba2+-alginate microbeads in cynomolgus monkeys. The results showed that the medications could only prevent fibrotic overgrowth on the surface of the implanted empty microbeads for as long as the medications were administered. This suggests that the extended use of immunosuppressants may have to be administrated to make the Ca2+/Ba2+-alginate microbeads biocompatible,which diminishes the goal of the encapsulation strategy(unpublished data).

    Incomplete immunoprotection is mainly caused by the uncontrollable passage of pro-inflammatory cytokines and other immunoreactive molecules with low molecular weights,such as IL-1β(17.5 KD)and TNF-α(51 KD)through the biopolymer membrane44-45.

    Therefore,strategies to block those cytokines have been studied in recent years to improve the graft survival after encapsulated islet transplantation. In a recent study,a peptide inhibitor for the cell surface IL-1 receptor(IL-1R)was conjugated to the hydrogel for capsules to block the interaction between the immobilized cells and the cytokines46. In another strategy,Sertoli cells were used in co-encapsulation with islets cells.These cells are located in the convoluted seminiferous tubules of testes and have been shown to inhibit T and B cell proliferation and IL-2 production47.Co-transplantation of islets with Sertoli cells were shown to have varying protective effects on graft survival in allo-48,concordant(rat to mouse)and discordant(fish to mouse)xeno-49-50,and autoimmune51transplant models. Study showed that the Sertoli cells improve the functional performance of alginate-PLL microencapsulated islets in xenotransplant models(rat-mouse)52. However,this approach has not advanced significantly enough to be used in clinical trials.

    Encapsulated islet transplantation in patients with T1DM

    Table 1 lists the clinical trials of encapsulated islets transplanted in patients with T1DM. Soon-Shiong et al. reported a successful human encapsulated islet transplant in a diabetic patient who was receiving immunosuppression for a functioning kidney graft17.In the study,a total of 15 000 IEQ/kg alginate-PLL encapsulated islets were implanted intraperitoneally.Insulin independence was demonstrated for 9 months after the procedure,with tight glycemic control noted.Scharp et al. subcutaneously implanted a PAN-PVC macroencapsulation device containing allogeneic islets into 9 patients53. The results concluded that macroencapsulated human islets could survive at the subcutaneous site and that semi-permeable membranes can be designed to protect against both allogeneic immune responses as well as the autoimmune reactions of patients with T1DM.

    Calafiore et al. transplanted alginate-PLO microcapsulated islets in a human clinical trial without immunosuppression20. In 2006,the results of the first two patients were published and both patients showed increased C-peptide serum levels,as a measure of islet graft function. Several weeks post transplantation,these two patients presented with an ephemeral incline in exogenous insulin consumption20. In 2011,the same group published the results of encapsulated islet transplantation in 4 patients,which included the follow-up results of the initial two patients reported in 2006 and two other patients transplanted afterwards54.So far,the results from 4 patients have been reported.In all cases the group observed no side effects of the grafting procedure,nor any evidence of immune sensitization. All patients exhibited a lower intake of exogenous insulin,approximately half of the pre-transplantation consumption levels.

    Tuch et al. transplanted allogeneic islets encapsulated in Ba2+-alginate microbeads into four diabetic patients without immunosuppression. C-peptide was present on day one after transplantation,but disappeared within a period of one to four weeks. In a recipient of multiple islet infusions,C-peptide was detected at 6 weeks after the third infusion and remained detectable for 30 months. Neither insulin requirement nor glycemic control was altered in any of the patients18.

    From 2005 to 2006,two companies,Amcyte,Inc.and Novocell,Inc. announced clinical trials involving encapsulated islet transplantation in patients with T1DM. Amcyte,Inc. planned to conduct clinical trials in twelve patients using islets encapsulated in alginate-PLL microcapsules. These microcapsules were further embedded into a macrocapsule for implantation.Another company,Novocell,Inc.(current name ViaCyte,Inc.),initiated phase 1/2 clinical trials of PEG-encapsulated islet allograft implantation in patients with T1DM. Twelve patients were enrolled in this clinical trial. However,this particular study was terminated. Currently,there is limited information available regarding these two clinical trials.most recent newsletter from the website,a registration study has been launched in 2013 for phase 2b/3 clinical trials,in which 30 patients were enrolled. The LCT product,DIABECEL@,is expected to be commercially available in 201619.

    Most recently,Jacobs-Tulleneers-Thevissen et al.published work on transplantation of Ca2+/Ba2+-alginate microbeads containing allogeneic islets in a patient56. The alginate microbeads were harvested 3 months after transplantation and were conglomerated in the peritoneal cavity. Another report announced a commercial product of the macroencapsulation device called the Cell Pouch SystemTM. This device can be subcutaneously implanted. The device has a unique ability of releasing anti-rejection drugs locally. The Cell Pouch SystemTMis currently preparing for clinical trials.

    The future perspectives

    At present,there is a large amount of islet encapsulation-related research in progress around the world trying to eliminate the use of immunosuppressants in patients with T1DM. This research is largely uncoordinated and a well-documented systematic analysis of the various capsule types has not been completed. The correlation between NHPs and human subjects in biocompatibility of device and function of transplanted islets is poorly demonstrated.Despite the numerous clinical trials conducted by academic institutes and biotechnological companies,encapsulated islet transplantation has not been perfected18-20,54,56. With regards to the mixed set of results,there are three main factors limiting the progression of microencapsulated islet transplantation towards clinical application. First,the variability of raw materials in the manufacturing process has impeded the development of a reliable microencapsulation system. Second,current biocompatibility testing relies heavily on in vivo rodent models,which does not

    Table 1 Encapsulated islet transplantation in patients with T1DM

    Xenotransplantation has attracted much attention in the field of islet transplantation. In the light of such consideration,transplantation of microencapsulated xenogeneic islets,especially porcine islets,has commenced in patients with T1DM. In 1996,Living Cell Technologies(LCT),a company based in New Zealand,initiated a clinical trial involving encapsulated porcine islet transplantation. In this trial,porcine islets were encapsulated in alginate-PLO microcapsules and implanted into the peritoneal cavity of patients without immunosuppression. Nine and a half years after transplantation,laparotomy of one of the patients showed the presence of microcapsules in the peritoneal cavity,some of which still contained live pig islet cells. However,the majority of cells appeared to be necrotic55. As of now,the company reported in their website that a total of 14 patients with T1DM were enrolled in the phase 1/2 clinical trial of DIABECEL@conducted in New Zealand and Russia19. The first four patients received approximately 10 000 IEQ/kg encapsulated islets and showed an average reduction of 76% in episodes of clinically significant hypoglycemia unawareness after 30-52 weeks of follow-up. Four patients from each of the second and third groups received 15 000 and 20 000 IEQ/kg of encapsulated islets respectively and the follow-up of these particular patients is ongoing. The last two patients have received a dose at 5 000 IEQ/kg and were enrolled to construct the dose ranging data needed to determine a target product profile for phase 3 clinical trials. Based on the strongly support patients with T1DM. Finally,there is a significant inconsistency in results observed among individual laboratories even with the use of similar biomaterials and experimental approaches.

    Taking all these obstacles into account,the development of a centralized in vitro and in vivo testing center in the future would allow for a more comprehensive,consistent,and species-specific examination of biocompatibility for the encapsulation system. A collaborative consortium may need to be organized,which should lead to the standardization in material selections,techniques,animal models,and procedures. Under active collaboration between research facilities,the end goal of providing islet encapsulation as a viable cure for patients with T1DM without immunosuppressant would be achievable.

    Acknowledgements

    The author would like to thank Dr. Igor Lacik and Dr.Berit L. Strand for sharing their knowledge of islet encapsulation and Dr. James McGarrigle for reviewing and editing the manuscript.

    午夜精品一区二区三区免费看| av在线蜜桃| 免费高清在线观看视频在线观看| 久久人人爽人人爽人人片va| 国产亚洲av嫩草精品影院| 超碰97精品在线观看| 国产欧美日韩精品一区二区| 22中文网久久字幕| 少妇的逼好多水| 日韩免费高清中文字幕av| 在线亚洲精品国产二区图片欧美 | 97人妻精品一区二区三区麻豆| 国产成人精品婷婷| 大香蕉97超碰在线| 精品一区二区三卡| 日本免费在线观看一区| 777米奇影视久久| av卡一久久| 女的被弄到高潮叫床怎么办| www.av在线官网国产| 国产午夜精品久久久久久一区二区三区| 亚洲国产欧美人成| 婷婷色综合www| 一本一本综合久久| 国产精品久久久久久精品电影| 日韩大片免费观看网站| 欧美国产精品一级二级三级 | 欧美日韩亚洲高清精品| 欧美高清性xxxxhd video| 亚洲天堂国产精品一区在线| 欧美一级a爱片免费观看看| 国产成人a区在线观看| 久久久精品免费免费高清| 黄色欧美视频在线观看| 赤兔流量卡办理| 久久久久网色| 精品一区二区三区视频在线| 一级黄片播放器| 狠狠精品人妻久久久久久综合| 久久精品国产亚洲网站| 亚洲美女搞黄在线观看| 蜜桃亚洲精品一区二区三区| 国产v大片淫在线免费观看| 日本三级黄在线观看| 乱码一卡2卡4卡精品| 99热这里只有是精品50| 人人妻人人看人人澡| 尾随美女入室| 夫妻性生交免费视频一级片| 永久网站在线| 在线观看av片永久免费下载| 国产精品成人在线| 91aial.com中文字幕在线观看| 又大又黄又爽视频免费| 亚洲国产欧美在线一区| 嫩草影院新地址| 欧美性猛交╳xxx乱大交人| 亚洲性久久影院| 国产伦理片在线播放av一区| 大香蕉久久网| 不卡视频在线观看欧美| av天堂中文字幕网| 永久免费av网站大全| 亚洲综合色惰| 午夜福利视频1000在线观看| 日韩欧美一区视频在线观看 | 男女无遮挡免费网站观看| av在线蜜桃| 国产男女内射视频| 欧美丝袜亚洲另类| 看免费成人av毛片| 我的女老师完整版在线观看| 美女cb高潮喷水在线观看| 真实男女啪啪啪动态图| 国产午夜福利久久久久久| av又黄又爽大尺度在线免费看| 久久国内精品自在自线图片| 可以在线观看毛片的网站| 成人毛片a级毛片在线播放| 精品久久久久久久久av| 最近的中文字幕免费完整| 赤兔流量卡办理| 日产精品乱码卡一卡2卡三| 青春草亚洲视频在线观看| 啦啦啦啦在线视频资源| 日本熟妇午夜| 亚洲精品一二三| 国产精品国产三级专区第一集| 国产高清国产精品国产三级 | 91狼人影院| 亚洲自拍偷在线| av在线播放精品| 亚洲人成网站在线播| 久久女婷五月综合色啪小说 | 91精品国产九色| 九草在线视频观看| 日本wwww免费看| videossex国产| 日本一本二区三区精品| 1000部很黄的大片| 国产精品爽爽va在线观看网站| 秋霞在线观看毛片| 伦精品一区二区三区| 精华霜和精华液先用哪个| 久久久久久久精品精品| 精品人妻一区二区三区麻豆| 在线a可以看的网站| 最近最新中文字幕免费大全7| 毛片女人毛片| 免费看不卡的av| 国产精品无大码| 亚洲aⅴ乱码一区二区在线播放| 久久精品国产a三级三级三级| 国产高清不卡午夜福利| 大片电影免费在线观看免费| 成年免费大片在线观看| 99视频精品全部免费 在线| xxx大片免费视频| 最近2019中文字幕mv第一页| 亚洲经典国产精华液单| 国产国拍精品亚洲av在线观看| 国产 精品1| 97超碰精品成人国产| 国产精品福利在线免费观看| 最近手机中文字幕大全| kizo精华| 美女国产视频在线观看| 97精品久久久久久久久久精品| 人人妻人人爽人人添夜夜欢视频 | 三级经典国产精品| 亚洲国产欧美人成| 蜜桃亚洲精品一区二区三区| 两个人的视频大全免费| 一区二区三区四区激情视频| 国产免费又黄又爽又色| 亚洲精品日韩av片在线观看| 国模一区二区三区四区视频| 亚洲三级黄色毛片| 婷婷色综合大香蕉| 国产人妻一区二区三区在| 97超碰精品成人国产| 日韩中字成人| 在线免费十八禁| 赤兔流量卡办理| 亚洲天堂av无毛| 97热精品久久久久久| 日韩视频在线欧美| 男女下面进入的视频免费午夜| 一级毛片我不卡| 欧美潮喷喷水| 精品国产三级普通话版| 51国产日韩欧美| 特级一级黄色大片| 日韩av免费高清视频| 成人鲁丝片一二三区免费| 国产精品.久久久| 国产精品国产三级国产av玫瑰| 久久久久精品性色| 一个人看的www免费观看视频| 国产精品久久久久久久久免| 国产熟女欧美一区二区| 久久精品综合一区二区三区| av线在线观看网站| 亚洲av中文av极速乱| 一区二区三区四区激情视频| 秋霞伦理黄片| 免费观看a级毛片全部| 观看美女的网站| 丝瓜视频免费看黄片| 亚洲精华国产精华液的使用体验| 日日撸夜夜添| 女人被狂操c到高潮| 国产老妇女一区| 一级毛片电影观看| videos熟女内射| 男女边摸边吃奶| av国产精品久久久久影院| 中文在线观看免费www的网站| 夜夜看夜夜爽夜夜摸| 有码 亚洲区| 特大巨黑吊av在线直播| 久久热精品热| 日韩欧美精品免费久久| 亚洲无线观看免费| 午夜激情久久久久久久| 成人鲁丝片一二三区免费| 在线天堂最新版资源| 91久久精品国产一区二区三区| 亚洲av不卡在线观看| 身体一侧抽搐| 午夜福利视频精品| 91精品一卡2卡3卡4卡| 精品久久久久久电影网| 成年免费大片在线观看| 亚洲精品aⅴ在线观看| 日本av手机在线免费观看| 国产综合懂色| 免费观看a级毛片全部| 男人和女人高潮做爰伦理| 中国美白少妇内射xxxbb| 国产成人免费观看mmmm| 蜜桃亚洲精品一区二区三区| 亚洲精品自拍成人| av国产久精品久网站免费入址| 日韩欧美一区视频在线观看 | 一区二区三区精品91| 18禁在线无遮挡免费观看视频| 国产伦精品一区二区三区四那| 日韩伦理黄色片| 中文乱码字字幕精品一区二区三区| 在线精品无人区一区二区三 | 午夜爱爱视频在线播放| 国产高清不卡午夜福利| av在线播放精品| 男女无遮挡免费网站观看| 精品久久久久久久久亚洲| 麻豆成人午夜福利视频| 欧美日韩综合久久久久久| 久久影院123| 精品人妻一区二区三区麻豆| 五月伊人婷婷丁香| 国产精品国产三级国产专区5o| 伦理电影大哥的女人| 久久久国产一区二区| 国产亚洲一区二区精品| 日韩人妻高清精品专区| 一区二区三区免费毛片| 伊人久久精品亚洲午夜| 狂野欧美激情性xxxx在线观看| 中文字幕亚洲精品专区| 美女脱内裤让男人舔精品视频| 日本午夜av视频| .国产精品久久| 日韩av免费高清视频| 亚洲av电影在线观看一区二区三区 | 国产成人a∨麻豆精品| 国产欧美日韩一区二区三区在线 | 日本与韩国留学比较| 午夜免费鲁丝| 精品99又大又爽又粗少妇毛片| 波野结衣二区三区在线| 26uuu在线亚洲综合色| 久久韩国三级中文字幕| 国产欧美日韩一区二区三区在线 | 日韩中字成人| 国产av国产精品国产| 香蕉精品网在线| 精品酒店卫生间| 最新中文字幕久久久久| 久久精品久久精品一区二区三区| 热re99久久精品国产66热6| 伦精品一区二区三区| 国产一区二区三区av在线| 色哟哟·www| 男人爽女人下面视频在线观看| 可以在线观看毛片的网站| 永久免费av网站大全| 777米奇影视久久| 人妻少妇偷人精品九色| 国产探花在线观看一区二区| 我的老师免费观看完整版| 在线观看三级黄色| 国模一区二区三区四区视频| 国产乱人偷精品视频| 日韩一本色道免费dvd| 国精品久久久久久国模美| 欧美成人午夜免费资源| 伦理电影大哥的女人| 久久99热这里只有精品18| 偷拍熟女少妇极品色| 国产v大片淫在线免费观看| 岛国毛片在线播放| 成人黄色视频免费在线看| av国产精品久久久久影院| 国产91av在线免费观看| av福利片在线观看| 免费不卡的大黄色大毛片视频在线观看| 王馨瑶露胸无遮挡在线观看| 97在线人人人人妻| 你懂的网址亚洲精品在线观看| 爱豆传媒免费全集在线观看| 热99国产精品久久久久久7| 秋霞伦理黄片| 国产精品福利在线免费观看| 最近中文字幕高清免费大全6| 免费黄网站久久成人精品| 夫妻性生交免费视频一级片| 亚洲精品色激情综合| 99久国产av精品国产电影| 免费人成在线观看视频色| 欧美精品人与动牲交sv欧美| 91久久精品国产一区二区三区| 性色av一级| 黄色一级大片看看| 免费电影在线观看免费观看| 美女cb高潮喷水在线观看| 免费少妇av软件| 欧美高清性xxxxhd video| 日韩在线高清观看一区二区三区| 免费av毛片视频| 白带黄色成豆腐渣| 国产成人91sexporn| 免费观看的影片在线观看| 高清在线视频一区二区三区| 国产成人精品久久久久久| 自拍偷自拍亚洲精品老妇| 欧美性感艳星| 欧美高清性xxxxhd video| 精品国产一区二区三区久久久樱花 | 国产探花在线观看一区二区| 国产黄色免费在线视频| 99九九线精品视频在线观看视频| 国产精品国产三级国产专区5o| 日韩国内少妇激情av| 亚洲av成人精品一二三区| 毛片女人毛片| 亚洲人成网站在线观看播放| 国产精品成人在线| 在线观看免费高清a一片| 极品少妇高潮喷水抽搐| 日本熟妇午夜| 一本色道久久久久久精品综合| 好男人视频免费观看在线| 精品一区二区三卡| 神马国产精品三级电影在线观看| 天美传媒精品一区二区| 日本三级黄在线观看| 天堂中文最新版在线下载 | 亚洲精品第二区| 内射极品少妇av片p| 美女国产视频在线观看| 99久国产av精品国产电影| 97超碰精品成人国产| 亚洲国产av新网站| 国产片特级美女逼逼视频| 麻豆成人av视频| 亚洲伊人久久精品综合| 色婷婷久久久亚洲欧美| 国产精品99久久久久久久久| 少妇人妻久久综合中文| 中文乱码字字幕精品一区二区三区| 日韩在线高清观看一区二区三区| av国产免费在线观看| 一级毛片我不卡| 人妻 亚洲 视频| 亚洲激情五月婷婷啪啪| 欧美激情在线99| 99热这里只有是精品50| 久久99蜜桃精品久久| videossex国产| 久热这里只有精品99| 亚洲精品成人久久久久久| 美女cb高潮喷水在线观看| 人人妻人人看人人澡| 成人国产麻豆网| 精品人妻熟女av久视频| 天天一区二区日本电影三级| 各种免费的搞黄视频| 午夜爱爱视频在线播放| 精品视频人人做人人爽| 蜜臀久久99精品久久宅男| 六月丁香七月| 亚洲av中文字字幕乱码综合| av国产免费在线观看| 一级毛片我不卡| 亚洲av成人精品一区久久| 国产精品国产三级专区第一集| av在线天堂中文字幕| av黄色大香蕉| 亚洲精品自拍成人| 精品久久久久久久末码| 亚洲三级黄色毛片| 欧美日韩在线观看h| 欧美成人a在线观看| 精品视频人人做人人爽| 日韩欧美精品v在线| 禁无遮挡网站| 伦精品一区二区三区| 最近最新中文字幕免费大全7| 亚洲精品成人av观看孕妇| 国产欧美亚洲国产| 99久久精品热视频| 最近的中文字幕免费完整| 看十八女毛片水多多多| 成人漫画全彩无遮挡| 日韩 亚洲 欧美在线| 久久久久久久久久成人| 精品一区二区免费观看| 黄色视频在线播放观看不卡| 黄色配什么色好看| 国产精品人妻久久久影院| 干丝袜人妻中文字幕| 亚洲国产高清在线一区二区三| 我要看日韩黄色一级片| 国产一区有黄有色的免费视频| 身体一侧抽搐| 免费观看性生交大片5| 欧美潮喷喷水| 免费av毛片视频| 成年免费大片在线观看| 你懂的网址亚洲精品在线观看| 日韩成人av中文字幕在线观看| 免费少妇av软件| 最新中文字幕久久久久| 乱系列少妇在线播放| 夫妻性生交免费视频一级片| 日韩强制内射视频| 日本一本二区三区精品| 久久国产乱子免费精品| 在线 av 中文字幕| 人妻一区二区av| 久久久国产一区二区| 中文字幕亚洲精品专区| 国产乱人视频| 一级毛片我不卡| 麻豆成人av视频| 欧美精品国产亚洲| 如何舔出高潮| 亚洲av欧美aⅴ国产| 六月丁香七月| 小蜜桃在线观看免费完整版高清| 久久久成人免费电影| 男人狂女人下面高潮的视频| 久久久久久九九精品二区国产| 午夜福利视频精品| 18+在线观看网站| 菩萨蛮人人尽说江南好唐韦庄| 韩国av在线不卡| 永久网站在线| 免费观看无遮挡的男女| 国产又色又爽无遮挡免| 大码成人一级视频| 极品少妇高潮喷水抽搐| 日本与韩国留学比较| 在线 av 中文字幕| 网址你懂的国产日韩在线| 久久ye,这里只有精品| 国产色婷婷99| 成人黄色视频免费在线看| 久久国内精品自在自线图片| 久久这里有精品视频免费| 九九久久精品国产亚洲av麻豆| 国产亚洲一区二区精品| 1000部很黄的大片| 97热精品久久久久久| 欧美人与善性xxx| 夫妻午夜视频| tube8黄色片| 3wmmmm亚洲av在线观看| 亚洲欧美日韩另类电影网站 | 又黄又爽又刺激的免费视频.| 国产精品福利在线免费观看| 麻豆成人午夜福利视频| 国产高清不卡午夜福利| 69人妻影院| 亚洲精华国产精华液的使用体验| 亚洲精品乱久久久久久| 熟妇人妻不卡中文字幕| 日本与韩国留学比较| 国产美女午夜福利| 精品国产露脸久久av麻豆| 校园人妻丝袜中文字幕| 国产色婷婷99| 最近最新中文字幕免费大全7| 国产欧美日韩一区二区三区在线 | 99久久中文字幕三级久久日本| 女的被弄到高潮叫床怎么办| 97人妻精品一区二区三区麻豆| 中文字幕亚洲精品专区| 黄片无遮挡物在线观看| av女优亚洲男人天堂| 黄色日韩在线| 69人妻影院| 国产伦理片在线播放av一区| 男女边吃奶边做爰视频| 又爽又黄无遮挡网站| 黄色怎么调成土黄色| 国产日韩欧美在线精品| 男女下面进入的视频免费午夜| 最近的中文字幕免费完整| 三级经典国产精品| 啦啦啦中文免费视频观看日本| 欧美高清成人免费视频www| 我的女老师完整版在线观看| 蜜桃亚洲精品一区二区三区| 男女啪啪激烈高潮av片| 黄色怎么调成土黄色| av在线亚洲专区| 欧美精品国产亚洲| 九九爱精品视频在线观看| 欧美日韩视频精品一区| 韩国av在线不卡| 亚洲精品aⅴ在线观看| 一级毛片我不卡| 黄色日韩在线| 色哟哟·www| 夜夜爽夜夜爽视频| 亚洲av.av天堂| 国产乱人偷精品视频| 日本wwww免费看| 国产精品久久久久久精品古装| 国产黄色免费在线视频| 国产精品嫩草影院av在线观看| 黄色日韩在线| 国产av国产精品国产| 精品少妇黑人巨大在线播放| 久久久久久久午夜电影| 天堂网av新在线| 18禁裸乳无遮挡动漫免费视频 | 国产真实伦视频高清在线观看| 亚洲精品成人av观看孕妇| 欧美精品人与动牲交sv欧美| 亚洲最大成人手机在线| 国产男女超爽视频在线观看| av在线播放精品| 特级一级黄色大片| 最近中文字幕高清免费大全6| 亚洲国产精品999| 精品一区二区免费观看| 亚洲精品国产av蜜桃| 亚洲精品日韩av片在线观看| 美女高潮的动态| 免费高清在线观看视频在线观看| 免费黄色在线免费观看| 国内少妇人妻偷人精品xxx网站| 久久国内精品自在自线图片| 熟女电影av网| 欧美成人a在线观看| 久久久久久久久久成人| 国产综合精华液| 熟女av电影| 深爱激情五月婷婷| 青春草视频在线免费观看| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 人妻 亚洲 视频| a级毛片免费高清观看在线播放| 在线观看一区二区三区激情| 亚洲av男天堂| 观看免费一级毛片| 18禁裸乳无遮挡动漫免费视频 | 成人午夜精彩视频在线观看| 日本猛色少妇xxxxx猛交久久| 欧美潮喷喷水| 国产视频首页在线观看| 亚洲欧美成人精品一区二区| 精品一区在线观看国产| 免费看不卡的av| 18禁在线播放成人免费| 麻豆成人av视频| 一区二区三区四区激情视频| 国产成人freesex在线| 国产高清有码在线观看视频| 亚洲欧美日韩东京热| 国产免费视频播放在线视频| 成年版毛片免费区| 好男人视频免费观看在线| 99精国产麻豆久久婷婷| 午夜福利视频1000在线观看| 欧美xxⅹ黑人| 成年人午夜在线观看视频| 日韩人妻高清精品专区| 人妻少妇偷人精品九色| 日韩av在线免费看完整版不卡| 免费黄色在线免费观看| 自拍偷自拍亚洲精品老妇| 国产精品久久久久久精品古装| 婷婷色综合大香蕉| 久久精品国产鲁丝片午夜精品| 免费电影在线观看免费观看| 国产色爽女视频免费观看| 五月玫瑰六月丁香| 中文字幕久久专区| 国产国拍精品亚洲av在线观看| 成人一区二区视频在线观看| 欧美另类一区| 国产淫语在线视频| 国产亚洲最大av| 色5月婷婷丁香| 日本av手机在线免费观看| 十八禁网站网址无遮挡 | 成人毛片60女人毛片免费| 国产精品久久久久久精品电影小说 | 亚洲欧美日韩另类电影网站 | 午夜免费观看性视频| 亚洲av.av天堂| 在线亚洲精品国产二区图片欧美 | 精品人妻视频免费看| 成人亚洲精品av一区二区| 美女国产视频在线观看| 丝袜喷水一区| 亚洲精品国产成人久久av| 国产伦在线观看视频一区| 国产高清有码在线观看视频| 国产老妇女一区| 久久久久精品性色| 欧美亚洲 丝袜 人妻 在线| 蜜桃亚洲精品一区二区三区| 亚洲国产精品专区欧美| 国产淫语在线视频| 欧美性猛交╳xxx乱大交人| 日韩,欧美,国产一区二区三区| 王馨瑶露胸无遮挡在线观看| 日本黄大片高清| 狂野欧美激情性bbbbbb| 精品久久国产蜜桃| 日韩一区二区视频免费看| 国产视频首页在线观看| 岛国毛片在线播放| 高清欧美精品videossex| 中文字幕av成人在线电影| 成年免费大片在线观看| 日韩制服骚丝袜av| 男女无遮挡免费网站观看| 免费大片18禁| 免费av不卡在线播放|